Hypercoagulability state and endotelial injury in stable chronic obstructive pulmonary disease patients
Keywords:
Hipercoagulabilidad. Daño endothelial. EPOC.Abstract
COPD is currently the fourth cause of death in our country; the main causal agent of the disease is tobacco whose effects on the bronchial tree are not limited to the lung parenchyma. The action of tobacco injures the endothelial wall, which could contribute to lung thrombosis, ischemic events or secondary pulmonary hypertension. Our work investigates the existence of a prothombotic state in these patients, characterized by the activation of clotting and endothelial injury, comparing the values of biochemical markers between COPD patients and healthy volunteers. Fifty-one patients with COPD and a group of 30 healthy volunteers of similar ages were selected and fibrinogen, D-dimer, factor VIII and von Willebrand factor (FvW:Ag and FvW:Rico) levels were compared. We found an increase of all markers in the patient group compared to the healthy control group. The differences found were statistically significant in all cases (p<0.05). COPD is characterized by a state of hypercoagulability and endothelial injury that they could contribute to the development of vascular complications such as lung thrombosis, ischemic events or secondary pulmonary hypertension.Downloads
References
1. PAUWELS RA, BUIST AS, MA P, JENKINS CR, HURD SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization global Initiative for chronic obstructive lung disease (GOLD): executive summary. Respir Care 2001; 46: 798-825.
2. KRIEF B. Impacto social y económico de la EPOC en España. Farmacoeconomía 1996; 5: 8-19.
3. SORIANO JB, ANCOCHEA J, MIRAVITLLES M, GARCÍA-RÍO F, DURAN E, MUÑOZ L et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J 2009 Dec 8 [Epub ahead of print].
https://doi.org/10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A4527
4. SOLER JJ, SÁNCHEZ L, LATORRE M, ALAMAR J, ROMÁN P, PERPIÑÁ M. Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario. Arch Bronconeumol 2001; 37: 375-381.
https://doi.org/10.1016/S0300-2896(01)78818-7
5. HIGENBOTTAM T. Pathophysiology of pulmonary hypertension; a role for endothelial dysfunction. Chest 1994; 105 (Suppl): 7S-12S.
https://doi.org/10.1378/chest.105.2_Supplement.7S
6. LOSCALZO J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med 1992; 327: 117-119.
https://doi.org/10.1056/NEJM199207093270209
7. ALESSANDRI C, BASILI S, VIOLI S, FERRONI P, GAZZANIGA PP, CORDOVA C et al. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994; 72: 343-346.
https://doi.org/10.1055/s-0038-1648868
8. PEINADO VI, PIZARRO S, BARBERÁ JA. Pulmonary vascular involvement in COPD. Chest 2008; 134: 808-814.
https://doi.org/10.1378/chest.08-0820
9. BUDHIRAJA R, TUDER R, HASSOUN P. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
https://doi.org/10.1161/01.CIR.0000102381.57477.50
10. National committee for clinical laboratory standards. One stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) test; Approved guideline, NCCLS Document H47-A, vol. 16 (3).
11. NEWMAN D, HENNEBERRY H, PRICE C. Particle enhanced light scattering immunoassay. Ann Clin Biochem 1992; 29: 22-42.
https://doi.org/10.1177/000456329202900104
12. METZMANN E. Protein quantitation on both branches of the Heidelberg curve by monitoring the kinetic of immunoprecipitation. Behring institute mitteilungen 1985; 78: 167-175.
13. FISHMAN A. Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385-391.
https://doi.org/10.1016/S0272-5231(05)70278-1
14. SIMONNEAU G, GALIE N, RUBIN L, LANGLEBEN D, SEEGER W, DOMENIGHETTI G et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
https://doi.org/10.1016/j.jacc.2004.02.037
15. MODESTO M, NAUFFAL D, ANSÓTEGUI E, MENÉNDEZ R, BALLESTA A, TOUZA R et al. Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease? Arch Bronconeumol 2006 Mar; 42: 130-134.
https://doi.org/10.1016/S1579-2129(06)60131-6
16. KOENIG W. Fibrinogen in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609.
https://doi.org/10.1055/s-0037-1613566
17. DANISH J, LEWINGTON S, THOMPSON SG, LOWE GD, COLLINS R, KOSTIS JB et al. Fibrinogen Studies Collaboration. Fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-1809.
https://doi.org/10.1001/jama.294.14.1799
18. AIBAR M.A. Estado protrombótico e hipertensión pulmonar en pacientes con EPOC [tesis doctoral . Zaragoza: Universidad de Zaragoza, 2005.
19. PETER K. MACCALLUM. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2005; 2: 34-43
https://doi.org/10.1513/pats.200406-036MS
20. WELSH CH, HASSELL KL, BADESCH DB, KRESSIN DC, MARLAR RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-717.
https://doi.org/10.1378/chest.110.3.710
21. FOLSOM A. Haemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86: 366-373.
https://doi.org/10.1055/s-0037-1616234
22. PARENT F, MAITRE S, MEYER G, RAHERISON C, MAL H, LANCAR R et al. Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study. Thromb Res 2007; 120: 195-200.
https://doi.org/10.1016/j.thromres.2006.09.012
23. KATSUMURA Y, OHTSUBO K. Association between pulmonary microthromboembolism and coagulation variables in hypercoagulable states: an autopsy study. Respirology 1999; 4: 239-243.
https://doi.org/10.1046/j.1440-1843.1999.00181.x
24. MCNEIL K, DUNNING J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart 2007; 93: 1152-1158.
https://doi.org/10.1136/hrt.2004.053603
25. RAMOS F, BATLLE J, LÓPEZ BORRASCA A. Mecanismos de alteración funcional del factor von willebrand. Med Clin (Barc) 1989; 92: 588-594.
26. WAGNER D, BONFANTI R. Von Willebrand factor and the endothelium. Mayo Clin Proc 1991; 66: 621-627.
https://doi.org/10.1016/S0025-6196(12)60522-9
27. PENNY WF, WEINSTEN M, SALZMAN EW, WARE A. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation 1991; 83: 1630-1636.
https://doi.org/10.1161/01.CIR.83.5.1630
28. CHAMBERS DC, BOLDY DA, AYRES JG. Chronic respiratory symptoms, von Willebrand factor and longitudinal decline in FEV1. Respir Med 1999; 93: 726-733.
https://doi.org/10.1016/S0954-6111(99)90040-9
29. TRACY RP, ARNOLD AM, ETTINGER W, FRIED L, MEILANH E, SAVAGE P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. The results from the cardiovascular health study. Arterioscler Thomb 1999; 19: 1776-1783.
https://doi.org/10.1161/01.ATV.19.7.1776
30. TAPSON VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 71-77.
https://doi.org/10.1513/pats.200407-038MS
31. BONDERMAN D, TURECEK PL, JAKOWITSCH J, WELTERMANN A, ADLBRECHT C, SCHNEIDER B et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90: 372-376.
https://doi.org/10.1160/TH03-02-0067
32. LANG I, KERR K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 568-570.
https://doi.org/10.1513/pats.200605-108LR
33. ERKEKOL O, ULU A, NUMANOGLU N, AKAR N. High plasma levels of factor VIII: An important risk factor for isolated pulmonary embolism. Respirology 2006; 11: 70-74.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
